- Home
- BY vs SNDX Comparison
BY vs SNDX Comparison
Compare BY & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- SNDX
- Stock Information
- Founded
- BY 1914
- SNDX 2005
- Country
- BY United States
- SNDX United States
- Employees
- BY N/A
- SNDX N/A
- Industry
- BY Major Banks
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- SNDX Health Care
- Exchange
- BY Nasdaq
- SNDX Nasdaq
- Market Cap
- BY 1.1B
- SNDX 974.9M
- IPO Year
- BY 2017
- SNDX 2016
- Fundamental
- Price
- BY $24.18
- SNDX $11.54
- Analyst Decision
- BY Hold
- SNDX Strong Buy
- Analyst Count
- BY 3
- SNDX 10
- Target Price
- BY $33.67
- SNDX $36.20
- AVG Volume (30 Days)
- BY 204.4K
- SNDX 1.9M
- Earning Date
- BY 04-24-2025
- SNDX 05-07-2025
- Dividend Yield
- BY 1.65%
- SNDX N/A
- EPS Growth
- BY 3.00
- SNDX N/A
- EPS
- BY 2.75
- SNDX N/A
- Revenue
- BY $379,856,000.00
- SNDX $23,680,000.00
- Revenue This Year
- BY $14.42
- SNDX $286.51
- Revenue Next Year
- BY $5.03
- SNDX $120.86
- P/E Ratio
- BY $8.79
- SNDX N/A
- Revenue Growth
- BY 7.52
- SNDX N/A
- 52 Week Low
- BY $19.82
- SNDX $9.66
- 52 Week High
- BY $32.89
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- BY 39.74
- SNDX 44.37
- Support Level
- BY $22.63
- SNDX $9.66
- Resistance Level
- BY $24.10
- SNDX $11.61
- Average True Range (ATR)
- BY 1.05
- SNDX 1.01
- MACD
- BY -0.02
- SNDX 0.02
- Stochastic Oscillator
- BY 36.73
- SNDX 56.12
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.